Thomas Moreau

Thomas Moreau

Auto-generated profile, based on publicly available information

Thomas Moreau

INRIA, Université Paris-Saclay, CEA, Palaiseau, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2022 in Journal of Neural Engineering
Verified
Journal Article
Closed access
CRCédric Rommel
Cédric Rommel
JPJoseph Paillard
Joseph Paillard
TMThomas Moreau
Thomas Moreau
AGAlexandre Gramfort
Alexandre Gramfort
Objective. The use of deep learning for electroencephalography (EEG) classification tasks has been rapidly growing in the last years, yet its application has been limited by the relatively small size of EEG datasets. Data augmentation, which consists in artificially increasing the size of the dataset during training, can be employed to alleviate this problem. While a few augmentation transformations for EEG data have been proposed in the literature, their positive impact on performance is often evaluated on a single dataset and compared to one or two competing augmentation methods. This work proposes to better validate the existing data augmentation approaches through a unified and exhaustive analysis. Approach. We compare quantitatively 13 different augmentations with two different predictive tasks, datasets and models, using three different types of experiments. Main results. We demonstrate that employing the adequate data augmentations can bring up to 45% accuracy improvements in low data regimes compared to the same model trained without any augmentation. Our experiments also show that there is no single best augmentation strategy, as the good augmentations differ on each task. Significance. Our results highlight the best data augmentations to consider for sleep stage classification and motor imagery brain–computer interfaces. More broadly, it demonstrates that EEG classification tasks benefit from adequate data augmentation.

19 November 2018 in Sensors
Verified
Journal Article
Open access
PDF file
LOLaurent Oudre
Laurent Oudre
RBRémi Barrois-Müller
Rémi Barrois-Müller
TMThomas Moreau
Thomas Moreau
CTCharles Truong
Charles Truong
AJAliénor Vienne Jumeau
Aliénor Vienne Jumeau
PVPierre-Paul Vidal
Pierre-Paul Vidal
This article presents a method for step detection from accelerometer and gyrometer signals recorded with Inertial Measurement Units (IMUs). The principle of our step detection algorithm is to recognize the start and end times of the steps in the signal thanks to a predefined library of templates. The algorithm is tested on a database of 1020 recordings, composed of healthy subjects and patients with various neurological or orthopedic troubles. Simulations on more than 40,000 steps show that the template-based method achieves remarkable results with a 98% recall and a 98% precision. The method adapts well to pathological subjects and can be used in a medical context for robust step estimation and gait characterization.

1 November 2021 in NeuroImage
Verified
Journal Article
Open access
HCHamza Cherkaoui
Hamza Cherkaoui
TMThomas Moreau
Thomas Moreau
AHAbderrahim Halimi
Abderrahim Halimi
CLClaire Leroy
Claire Leroy
PCPhilippe Ciuciu
Philippe Ciuciu
Whole brain estimation of the haemodynamic response function (HRF) in functional magnetic resonance imaging (fMRI) is critical to get insight on the global status of the neurovascular coupling of an individual in healthy or pathological condition. Most of existing approaches in the literature works on task-fMRI data and relies on the experimental paradigm as a surrogate of neural activity, hence remaining inoperative on resting-stage fMRI (rs-fMRI) data. To cope with this issue, recent works have performed either a two-step analysis to detect large neural events and then characterize the HRF shape or a joint estimation of both the neural and haemodynamic components in an univariate fashion. In this work, we express the neural activity signals as a combination of piece-wise constant temporal atoms associated with sparse spatial maps and introduce an haemodynamic parcellation of the brain featuring a temporally dilated version of a given HRF model in each parcel with unknown dilation parameters. We formulate the joint estimation of the HRF shapes and spatio-temporal neural representations as a multivariate semi-blind deconvolution problem in a paradigm-free setting and introduce constraints inspired from the dictionary learning literature to ease its identifiability. A fast alternating minimization algorithm, along with its efficient implementation, is proposed and validated on both synthetic and real rs-fMRI data at the subject level. To demonstrate its significance at the population level, we apply this new framework to the UK Biobank data set, first for the discrimination of haemodynamic territories between balanced groups (n=24 individuals in each) patients with an history of stroke and healthy controls and second, for the analysis of normal aging on the neurovascular coupling. Overall, we statistically demonstrate that a pathology like stroke or a condition like normal brain aging induce longer haemodynamic delays in certain brain areas (e.g. Willis polygon, occipital, temporal and frontal cortices) and that this haemodynamic feature may be predictive with an accuracy of 74 % of the individual's age in a supervised classification task performed on n=459 subjects.

19 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
ESEmilie Sbidian
Emilie Sbidian
JJJulie Josse
Julie Josse
GLGuillaume Lemaitre
Guillaume Lemaitre
IMImke Meyer
Imke Meyer
MBMélodie Bernaux
Mélodie Bernaux
EAEtienne Audureau
Etienne Audureau
Objective: To assess the clinical effectiveness of oral hydroxychloroquine (HCQ) with or without azithromycin (AZI) in preventing death or leading to hospital discharge. Design: Retrospective cohort study. Setting: An analysis of data from electronic medical records and administrative claim data from the French Assistance Publique - Hôpitaux de Paris (AP-HP) data warehouse, in 39 public hospitals, Ile-de-France, France. Participants: All adult inpatients with at least one PCR-documented SARS-CoV-2 RNA from a nasopharyngeal sample between February 1 st , 2020 and April 6 th , 2020 were eligible for analysis. The study population was restricted to patients who did not receive COVID-19 treatments assessed in ongoing trials, including antivirals and immunosuppressive drugs. End of follow-up was defined as the date of death, discharge home, day 28 after admission, whichever occurred first, or administrative censoring on May 4, 2020. Intervention: Patients were further classified into 3 groups: (i) receiving HCQ alone, (ii) receiving HCQ together with AZI, and (iii) receiving neither HCQ nor AZI. Exposure to a HCQ/AZI combination was defined as a simultaneous prescription of the 2 treatments (more or less one day). Main outcome measures: The primary outcome was all-cause 28-day mortality as a time-to-event endpoint under a competing risks survival analysis framework. The secondary outcome was 28-day discharge home. Augmented inverse probability of treatment weighted (AIPTW) estimates of the average treatment effect (ATE) were computed to account for confounding. Results: A total of 4,642 patients (mean age: 66.1 ± 18; males: 2,738 (59%)) were included, of whom 623 (13.4%) received HCQ alone, 227 (5.9%) received HCQ plus AZI, and 3,792 (81.7%) neither drug. Patients receiving ‘HCQ alone’ or ‘HCQ plus AZI’ were more likely younger, males, current smokers and overall presented with slightly more co-morbidities (obesity, diabetes, any chronic pulmonary diseases, liver diseases), while no major difference was apparent in biological parameters. After accounting for confounding, no statistically significant difference was observed between the ‘HCQ’ and ‘Neither drug’ groups for 28-day mortality: AIPTW absolute difference in ATE was +1.24% (−5.63 to 8.12), ratio in ATE 1.05 (0.77 to 1.33). 28-day discharge rates were statistically significantly higher in the ‘HCQ’ group: AIPTW absolute difference in ATE (+11.1% [3.30 to 18.9]), ratio in ATE (1.25 [1.07 to 1.42]). As for the ‘HCQ+AZI’ vs neither drug, trends for significant differences and ratios in AIPTW ATE were found suggesting higher mortality rates in the former group (difference in ATE +9.83% [-0.51 to 20.17], ratio in ATE 1.40 [0.98 to 1.81];p=0.062). Conclusions: Using a large non-selected population of inpatients hospitalized for COVID-19 infection in 39 hospitals in France and robust methodological approaches, we found no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality. Our results suggested a possible excess risk of mortality associated with HCQ combined with AZI, but not with HCQ alone. Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies. Altogether, our findings further support the need to complete currently undergoing randomized clinical trials. WHAT THIS PAPER ADDS?: What is already known on this subject: - The use of Hydroxychloroquine (HCQ) or HCQ with azithromycin (AZI) has been associated with viral load reduction at 6 days in COVID-19 infected patients - No difference between HCQ and no-HCQ groups in terms of risk of death or need for mechanical ventilation was found in two large cohorts of hospitalized COVID-19 infected patients What this study adds: - Using a large non-selected population of inpatients hospitalized for COVID-19 infection in 39 hospitals in France and robust methodological approaches, we found no evidence for efficacy of HCQ on 28-day mortality - Our results suggest an excess risk of mortality in patients treated by a combination of HCQ and AZI, but not with HCQ alone - Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies

4 January 2022 in Biological Psychiatry Global Open Science
Verified
Journal Article
Open access
NHNicolas Hoertel
Nicolas Hoertel
MSMarina Sánchez-Rico
Marina Sánchez-Rico
PMPedro de la Muela
Pedro de la Muela
MAMiriam Abellán
Miriam Abellán
CBCarlos Blanco
Carlos Blanco
EZEric Zapletal
Eric Zapletal
Prior research suggests that psychiatric disorders could be linked to increased mortality among patients with COVID-19. However, whether all or specific psychiatric disorders are intrinsic risk factors of death in COVID-19 or whether these associations reflect the greater prevalence of medical risk factors in people with psychiatric disorders has yet to be evaluated. We performed an observational, multicenter, retrospective cohort study to examine the association between psychiatric disorders and mortality among patients hospitalized for laboratory-confirmed COVID-19 at 36 Greater Paris University hospitals. Of 15,168 adult patients, 857 (5.7%) had an ICD-10 diagnosis of psychiatric disorder. Over a mean follow-up period of 14.6 days (SD = 17.9), 326 of 857 (38.0%) patients with a diagnosis of psychiatric disorder died compared with 1276 of 14,311 (8.9%) patients without such a diagnosis (odds ratio 6.27, 95% CI 5.40–7.28, p < .01). When adjusting for age, sex, hospital, current smoking status, and medications according to compassionate use or as part of a clinical trial, this association remained significant (adjusted odds ratio 3.27, 95% CI 2.78–3.85, p < .01). However, additional adjustments for obesity and number of medical conditions resulted in a nonsignificant association (adjusted odds ratio 1.02, 95% CI 0.84–1.23, p = .86). Exploratory analyses after the same adjustments suggested that a diagnosis of mood disorders was significantly associated with reduced mortality, which might be explained by the use of antidepressants. These findings suggest that the increased risk of COVID-19–related mortality in individuals with psychiatric disorders hospitalized for COVID-19 might be explained by the greater number of medical conditions and the higher prevalence of obesity in this population and not by the underlying psychiatric disease.

1 May 2019
Verified
Conference Paper
Closed access
HCHamza Cherkaoui
Hamza Cherkaoui
TMThomas Moreau
Thomas Moreau
AHAbderrahim Halimi
Abderrahim Halimi
PCPhilippe Ciuciu
Philippe Ciuciu
The estimation of the hemodynamic response function (HRF) in functional magnetic resonance imaging (fMRI) is critical to deconvolve a time-resolved neural activity and get insights on the underlying cognitive processes. Existing methods propose to estimate the HRF using the experimental paradigm (EP) in task fMRI as a surrogate of neural activity. These approaches induce a bias as they do not account for latencies in the cognitive responses compared to EP and cannot be applied to resting-state data as no EP is available. In this work, we formulate the joint estimation of the HRF and neural activation signal as a semi blind deconvolution problem. Its solution can be approximated using an efficient alternate minimization algorithm. The proposed approach is applied to task fMRI data for validation purpose and compared to a state-of-the-art HRF estimation technique. Numerical experiments suggest that our approach is competitive with others while not requiring EP information.